Tracers / [225Ac]Ac-DOTA-hu3F8

[225Ac]Ac-DOTA-hu3F8

Also written as [Ac-225]Ac-DOTA-hu3F8

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: preclinical
Syntheses indexed: 2

What it is

Compound class: radiolabeled humanized anti-GD2 monoclonal antibody (alpha-particle emitter labeled)
Target / mechanism: GD2 (disialoganglioside) PMID 41292310
Clinical application: Relapsed and refractory high-risk neuroblastoma PMID 41292310
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	DOTA-hu3F8	41292310 2025 J Med Chem
—	—	—	—	—	DOTA-hu3F8	38108831 2024 Eur J Nucl Med Mol Imaging The hu3F8 antibody was radiolabeled with actinium-225

Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-hu3F8, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 28: added indication(s) onc-sarcoma, onc-neuroblastoma from consolidated missing-rubric review.